
Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Friday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $1.46 per share for the year, down from their previous forecast of $1.51. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.34 EPS, Q1 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.47 EPS and FY2027 earnings at $1.60 EPS.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion.
View Our Latest Stock Analysis on Genmab A/S
Genmab A/S Stock Down 0.4%
Shares of NASDAQ GMAB opened at $53.87 on Tuesday. The stock has a market capitalization of $33.62 billion, a P/E ratio of 46.04, a PEG ratio of 2.18 and a beta of 0.73. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.45 and a quick ratio of 2.43. Genmab A/S has a one year low of $23.62 and a one year high of $59.97. The firm’s 50 day simple moving average is $40.46 and its two-hundred day simple moving average is $31.43.
Hedge Funds Weigh In On Genmab A/S
A number of institutional investors and hedge funds have recently modified their holdings of GMAB. Bessemer Group Inc. increased its position in Genmab A/S by 38.6% during the third quarter. Bessemer Group Inc. now owns 729 shares of the company’s stock valued at $26,000 after acquiring an additional 203 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in Genmab A/S in the second quarter worth about $31,000. Nykredit A S purchased a new position in Genmab A/S in the second quarter worth about $58,000. GAMMA Investing LLC boosted its position in Genmab A/S by 16.4% in the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after purchasing an additional 561 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 51.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,597 shares of the company’s stock valued at $123,000 after purchasing an additional 1,565 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.
Genmab A/S News Summary
These are some of the GMAB news items that stood out recently:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite reducing several earnings estimates.
- Neutral Sentiment: The company disclosed managerial-employee securities transactions, but the provided announcement details do not specify their direction or size, so the trading signal is unclear. Transactions with shares and linked securities in Genmab A/S
- Neutral Sentiment: Short-interest data is inconsistent: one report says short interest rose 46.4% to 9.66 million shares by October 30, while another lists zero shares for November 10. The October figure was about 1.6% of shares outstanding, with a 1.2-day cover ratio.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Read More
- Five stocks we like better than Genmab A/S
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
